cyc 202 has been researched along with HPV Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellinger, G; Biktasova, A; Gary, C; Hajek, M; Issaeva, N; Yarbrough, WG | 1 |
| Atanasova, GN; Isaeva, AR; Mitev, VI; Poumay, Y; Zhelev, N | 1 |
2 other study(ies) available for cyc 202 and HPV Infection
| Article | Year |
|---|---|
Selective antitumor activity of roscovitine in head and neck cancer.
Topics: Animals; Antineoplastic Agents; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Papillomaviridae; Papillomavirus Infections; Protein Kinase Inhibitors; Purines; Roscovitine; Xenograft Model Antitumor Assays | 2016 |
Effects of the CDK-inhibitor CYC202 on p38 MAPK, ERK1/2 and c-Myc activities in papillomavirus type 16 E6- and E7-transformed human keratinocytes.
Topics: Blotting, Northern; Blotting, Western; Cell Proliferation; Cell Transformation, Viral; Cells, Cultured; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Extracellular Signal-Regulated MAP Kinases; Human papillomavirus 16; Humans; Keratinocytes; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oncogene Proteins, Viral; p38 Mitogen-Activated Protein Kinases; Papillomavirus E7 Proteins; Papillomavirus Infections; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Purines; Repressor Proteins; Roscovitine; Signal Transduction | 2007 |